Compound ID | 319
SM-232721
Synonym(s): Research Programme-2-(Thiazol-2ylthio)-1β-Methylcarbapenem | SM 232721 | SM232721
Class: Beta-lactam
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci |
| Description: | A 1 beta-methylcarbapenems with a unique 4-substituted thiazol-2-ylthio moiety |
| Institute where first reported: | Roche, Switzerland; Sumitomo Pharmaceuticals (Dainippon Sumitomo Pharmaceuticals, Japan) |
| Year first mentioned: | 2001 |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/substance/273348421 |
| Citation: | https://doi.org/10.1128/aac.47.8.2471-2480.2003 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.